Tetsu Akiyama Selected Research

Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)

4/2015	Thr160 of Axin1 is critical for the formation and function of the β-catenin destruction complex.
8/2013	Differences in the localization of the adenomatous polyposis coli-Asef/Asef2 complex between adenomatous polyposis coli wild-type and mutant cells.
10/2011	Crystal structures of the armadillo repeat domain of adenomatous polyposis coli and its complex with the tyrosine-rich domain of Sam68.
1/2010	The adenomatous polyposis coli-associated guanine nucleotide exchange factor Asef is involved in angiogenesis.
8/2009	Adenomatous polyposis coli and Asef function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase.
8/2009	Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands.
7/2008	Ligand-dependent interaction between estrogen receptor alpha and adenomatous polyposis coli.
11/2007	Alpha-catenin is essential in intestinal adenoma formation.
2/2007	Crystal structure of the rac activator, Asef, reveals its autoinhibitory mechanism.
4/2006	Human scribble, a novel tumor suppressor identified as a target of high-risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous polyposis coli.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tetsu Akiyama Research Topics

Disease

29	Neoplasms (Cancer) 01/2022 - 06/2002
14	Carcinogenesis 01/2022 - 01/2004
14	Colorectal Neoplasms (Colorectal Cancer) 11/2016 - 06/2002
14	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 04/2015 - 06/2002
8	Colonic Neoplasms (Colon Cancer) 01/2020 - 05/2011
7	Carcinoma (Carcinomatosis) 06/2022 - 01/2007
6	Glioblastoma (Glioblastoma Multiforme) 10/2021 - 01/2014
5	Inflammation (Inflammations) 01/2020 - 09/2013
3	Hypersensitivity (Allergy) 03/2021 - 12/2019
3	Breast Neoplasms (Breast Cancer) 02/2009 - 09/2004
2	Autistic Disorder (Autism) 01/2022 - 08/2018
2	COVID-19 01/2022 - 01/2022
2	Infections 01/2022 - 11/2006
2	Mucositis 01/2020 - 12/2019
2	Asthma (Bronchial Asthma) 11/2019 - 01/2016
2	Endometriosis 03/2018 - 01/2015
2	Pathologic Processes 11/2016 - 11/2011
2	Hepatocellular Carcinoma (Hepatoma) 06/2008 - 06/2002
2	Adenoma (Adenomas) 11/2007 - 01/2007
2	T-Cell Leukemia (Leukemia, T Cell) 11/2006 - 01/2004
1	Ovarian Epithelial Carcinoma 06/2022
1	Ovarian Neoplasms (Ovarian Cancer) 02/2022
1	Hypoxia (Hypoxemia) 01/2022
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2022
1	Confusion (Bewilderment) 01/2022
1	Epilepsy (Aura) 01/2022
1	Fragile X Syndrome (Martin Bell Syndrome) 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Virus Diseases (Viral Diseases) 01/2022
1	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2021
1	Dysbiosis 01/2021
1	Leukemia 01/2020
1	Philadelphia Chromosome 01/2020
1	Ulcerative Colitis 01/2020
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 12/2019
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Dwarfism 08/2016
1	Micrognathism 08/2016

Drug/Important Bio-Agent (IBA)

14	beta CateninIBA 01/2010 - 06/2002
13	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2002
7	CateninsIBA 01/2022 - 11/2011
4	Transcription Factors (Transcription Factor)IBA 11/2016 - 06/2002
4	Guanine Nucleotide Exchange Factors (Guanine Nucleotide Exchange Factor)IBA 08/2013 - 02/2007
3	Biomarkers (Surrogate Marker)IBA 02/2022 - 03/2010
3	CytokinesIBA 01/2022 - 09/2013
3	MetalsIBA 03/2021 - 12/2019
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019 - 01/2004
3	Long Noncoding RNAIBA 01/2019 - 02/2016
3	LigandsIBA 04/2015 - 07/2008
3	Messenger RNA (mRNA)IBA 01/2013 - 03/2005
3	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 08/2009 - 11/2004
2	NickelIBA 01/2020 - 12/2019
2	RNA-Binding Proteins (RNA-Binding Protein)IBA 11/2019 - 01/2016
2	Antisense OligonucleotidesIBA 11/2019 - 01/2016
2	Sirtuin 2IBA 11/2018 - 01/2015
2	Biological ProductsIBA 11/2016 - 11/2011
2	UbiquitinIBA 02/2016 - 04/2006
2	Heterogeneous-Nuclear Ribonucleoprotein KIBA 01/2016 - 03/2015
2	ThymineIBA 01/2016 - 03/2005
2	ErbB Receptors (EGF Receptor)IBA 01/2016 - 08/2008
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 02/2015 - 08/2009
2	Guanylate KinasesIBA 12/2013 - 05/2007
2	Tyrosine (L-Tyrosine)FDA Link 10/2011 - 05/2011
2	Transforming Growth Factor beta (TGF-beta)IBA 08/2008 - 02/2004
2	Activins (Activin)IBA 08/2008 - 02/2004
2	TCF Transcription FactorsIBA 04/2007 - 02/2004
2	Carrier Proteins (Binding Protein)IBA 01/2007 - 12/2004
2	Oncogene Proteins (Oncogene Protein)IBA 04/2006 - 01/2004
1	Phosphates (Orthophosphate)IBA 06/2022
1	16S Ribosomal RNAIBA 02/2022
1	qingfei paidu decoctionIBA 01/2022
1	RNA Splicing FactorsIBA 01/2022
1	Adenosine Triphosphate (ATP)IBA 01/2022
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	N-Methylaspartate (NMDA)IBA 01/2022
1	Interleukin-8 (Interleukin 8)IBA 01/2022
1	RNA Helicases (RNA Helicase)IBA 01/2022
1	Interleukin-18 (Interleukin 18)IBA 01/2022
1	Metalloproteases (Metalloproteinases)IBA 01/2022
1	Small Cytoplasmic RNAIBA 10/2021
1	Histones (Histone)IBA 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	PalladiumIBA 01/2020
1	Ubiquitin-Specific ProteasesIBA 01/2020
1	ZincIBA 12/2019
1	SteroidsIBA 11/2019
1	CalicIBA 01/2019
1	Heterogeneous-Nuclear Ribonucleoprotein LIBA 01/2019
1	Small Interfering RNA (siRNA)IBA 01/2019
1	Lysine (L-Lysine)FDA Link 11/2018
1	Cell-Free Nucleic AcidsIBA 03/2018
1	Transcription Factor 3IBA 11/2016
1	Coat Protein Complex I (COPI)IBA 08/2016
1	Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA 03/2016
1	Transforming Growth Factor-beta Type II ReceptorIBA 03/2016
1	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2016
1	Stearoyl-CoA DesaturaseIBA 02/2016

Therapy/Procedure

10	Therapeutics 01/2022 - 08/2007
5	Drug Therapy (Chemotherapy) 06/2022 - 01/2010